Our previous study [21] reported that visfatin was highly expressed in breast cancer tissues and is associated with tumor size, ER negativity (−), PR (−), and poor disease-free/overall survival as well as low recurrence rates for hormone therapy. Here, ESR1 is linked to breast cancer.